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ABSTRACT 
Inhibition of some enzymes seems to be one of the therapeutic strategies for the management of certain diseases or conditions such as diabetes, 
Alzheimer’s disease, cancer and obesity. In this review, an updated information on the enzyme inhibitory activity of lichen extracts and lichen 
compounds by an intensive literature survey is presented. Crude solvent extracts and isolated compounds from lichens were sho wn to be 
effective in causing inhibition of several enzymes such as amylase, lipase, lipoxygenase, aromatase, cyclooxygenase, trypsin, β-glucoronidase, 
prolyl endopeptidase, monoamine oxidase, urease, tyrosinase, xanthine oxidase, Thioredoxin reductase, glucosidase, topoisomer ase, pancreatic 
elastase, phosphodiesterase, telomerase and acetylcholinesterase. Lichen metabolites such as usnic acid and its derivatives, lobaric acid, 
physodic acid, ramalin, protolichestrinic acid, salazinic acid, atranorin, evernic acid, zeorin, diffractic acid, psoromic ac id, methyl β-
orcinolcarboxylate, methylorsellinate, and anziaic acid were shown to be inhibitors of some enzymes. In conclusion, lichens can be employed as 
promising therapeutic agents in terms of their potential to inhibit the activity of certain enzymes that are involved in some diseases or 
disorders. In vitro culturing of lichen symbionts in optimized media can be carried out to isolate enzyme inhibitors in larger scale and to 
develop effective therapeutic agents.   
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Lichens are the ecologically stable, self-supporting and most 
successful symbiotic association between a phytosynthetic 
partner (photobiont; an inhabitant) comprising of an alga or 
a cyanobacterium and a fungal partner (mycobiont; an 
exhabitant) represented by an ascomycete or basidiomycete 
member. Mycobiont of majority of lichens belongs to 
Ascomycetes. Lichens are unique group of organisms as they 
appear as a distinct phenotype which is different from either 
partners. There are about 20000 species of lichens 
distributed worldwide. Lichens are ubiquitous in 
distribution (from arctic to tropical; from plains to high 
mountains) and occur in one of the four growth forms: 
crustose, squamulose, foliose and fruticose (Figure 1). 
Lichens appear to be the primary colonizers in many barren 
habitats. Lichens are slow growing organisms, adapt to 
extreme environmental conditions, and are able to grow on 
various substrates viz. bark (corticolous), rock (saxicolous), 
soil (terricolous), leaf (foliicolous), twigs (ramicolous), 
mosses (muscicolous) and plastic (plasticolous). Lichens 
have been considered as indicators of air pollution. Most 
lichens are sensitive to air pollution and disappear from 
regions with high air pollutants. Some lichen species are 
tolerant and accumulate pollutants in their thallus aiding in 
the study of extent of pollution in an area1-7.  
Lichens have potential utilization as food, spice, medicine, as 
source of dyes and as material for sacrificial fire. Lichens are 
used medicinally in various parts of the world. Traditional 
healers as well as certain indigenous systems of medicine 
employ several lichen species for therapy against diseases 
such as tuberculosis, diarrhea, vomiting, cough, bleeding, 
antidote, skin diseases, bronchial irritation, sore throat5,8-12. 
Lichens produce characteristic secondary metabolites 
(>1000 in number and termed often as lichen substances or 
lichen compounds) and most of these compounds do not 
occur in other organisms. Only a small number of such 
compounds (around 60) may be found in other fungi or 
higher plants. These metabolites majorly originate from 
secondary metabolism of the fungal partner. Metabolic 
pathways such as acetate-malonate pathway, shikimic acid 
pathway and mevalonic acid pathway are involved in the 
biosynthesis of lichen metabolites (Figure 2). These 
secondary metabolites are useful in lichen taxonomy. 
Besides, several lichen metabolites are responsible for the 
biological activities displayed by lichens2,13-25. 
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Figure 1: Major types of lichens (Photograph by Prashith Kekuda) 
 
Figure 2: Metabolic pathways involved in the synthesis of lichen metabolites21 
 
Enzymes are biocatalysts and are the key components of 
metabolism as they are involved in catalyzing biochemical 
reactions in the cell. However, the activity of certain enzymes 
(such as amylase, protein tyrosine phosphatase 1B, 
glucosidase, urease, and acetylcholinesterase) are known to 
result in certain pathological conditions such as diabetes, 
obesity, hypertension, congestive heart failure, gastric ulcer 
and cancer. Enzyme inhibitors have been extensively used as 
a treatment of such pathological conditions. Studies 
concerning discovery of enzyme inhibitors are gaining high 
importance nowadays because of certain negative effects 
that are associated with the use of existing drugs26-33. Table 1 
shows a list of targeted enzymes (for possible therapy) that 
are involved in certain pathological conditions. Natural 
products, including lichens and their metabolites, have been 
screened for enzyme inhibitory studies against various key 
enzymes of metabolism such as acetylcholinesterase, lipase, 
protein tyrosine phosphatase 1B, amylase, angiotensin-
converting enzyme, HMG CoA reductase, lipoxygenase, 
glucosidase, urease, tyrosinase, topoisomerase and xanthine 
oxidase28,34-42. In the present review, an intense literature 
survey was conducted to compile data available on the 
enzyme inhibitory activity of lichen extracts and lichen 
substances by referring journals, and various search engines 
viz. Google scholar, PubMed and ScienceDirect. 
  
Table 1: A list of some diseases or conditions and the enzymes targeted 
Disease/condition Enzyme targeted Reference 
Diabetes Amylase  Jayaraj et al.43 
Diabetes  Glucosidase van de Laar44 
Diabetes  Protein tyrosine phosphatase 1B Taylor and Hill45 
Hyperpigmentation  Tyrosinase  Verma et al.46 
Gout, hyperuricemia  Xanthine oxidase Pacher et al.47 
Gastric and urinary infections Urease  Follmer48 
Obesity  Pancreatic lipase Lunagariya et al.29 
Obesity  Protein tyrosine phosphatase 1B Taylor and Hill45 
Inflammatory diseases  Lipoxygenase  Steinhilber and Hofmann49 
Inflammatory diseases   Cyclooxygenase  Harris and Breyer50 
Inflammatory diseases  Prostaglandin E2 synthase-1 Psarra et al.51 
Inflammatory diseases Phosphodiesterase  Dastidar et al.52 
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Cancer  Telomerase  Kelland53 
Cancer  Fatty acid synthase  Zhang et al.54 
Cancer  Tyrosyl-DNA Phosphodiesterase 1 Dexheimer et al.55 
Cancer  DNA polymerase  Berdis56 
Cancer Polo-like kinase-1 Liu et al.57 
Cancer  Topoisomerase  Sinha58 
Cancer Rab geranylgeranyl transferase Sane et al.59 
Cancer  β-glucuronidase Lampe et al.60 
Cancer Aromatase Fabian61 
Cancer  Sulfatase  Shah et al.62 
Alzheimer’s disease  Cholinesterase  Grossberg63 
Cognitive disorders  Prolyl endopeptidase Männisto et al.64 
Atherosclerosis  Phospholipase A2 Rosenson and Hurt-Camejo65 
Diabetic peripheral neuropathy Aldose reductase Schemmel et al.66 
Hypertension and others Angiotensin-converting enzyme  White67 
Hypercholesteromia  HMG CoA reductase Pazzucconi et al.68 
Central nervous disorders Monoamine oxidase Entzeroth and Ratty69 
AIDS HIV-1 reverse transcriptase Castro et al.70 
Pancreatitis and others Trypsin  Brandl et al.71 
Tuberculosis  Arylamine-N-acetyltransferase  Westwood et al.72 
Tuberculosis  UDP-galactopyranose mutase Soltero-Higgin et al.73 
Cancer, neurodegenerative diseases  Thioredoxin reductase Saccoccia et al.74 
 
ENZYME INHIBITORY ACTIVITY OF LICHENS 
Solvent extracts and purified compounds of lichens were 
shown to be effective enzyme inhibitors. An intensive 
literature survey revealed the potential of lichens to inhibit a 
range of enzymes such as amylase, glucosidase, 
lipoxygenase, telomerase, prolyl endopeptidase, tyrosinase, 
cyclooxygenase, xanthine oxidase, monoamine oxidase, 
pancreatic lipase, trypsin, pancreatic elastase, 
acetylcholinesterase, Thioredoxin reductase, prostaglandin 
E2 synthase-1, protein tyrosine phosphatase 1B, 
phosphodiesterase and topoisomerase. A brief description 
on inhibitory effect of lichens against these enzymes is 
presented below. Structures of some enzyme inhibitors from 
lichens3,40,75-82 is shown in Figure 3 and Figure 4.  
 
 
Figure 3: Structures of some lichen metabolites having enzyme inhibitory activity 
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Figure 4: Structures of some lichen metabolites having enzyme inhibitory activity 
 
Amylase inhibitory activity 
Methanol extract of Caloplaca biatorina was shown to exhibit 
concentration dependent inhibition of α-amylase83. Various 
solvent extracts of lichens viz. Ramalina sinensis, 
Heterodermia leucomelos, Herpothallon sp. and Parmatorema 
reticulatum were tested against α-amylase. The extracts 
showed concentration dependent inhibitory activity against 
amylase84. Various solvent extracts of Parmelia perlata were 
screened for salivary amylase inhibitory activity. Highest and 
least inhibitory activity was observed in case of methanol 
extract (94.74% inhibition) and aqueous extract (40.80% 
inhibition) respectively85. Methanol and ethyl acetate 
extracts of two lichens viz. Physcia aipolia and Flavoparmelia 
caperata were effective in causing dose dependent inhibition 
of alpha amylase86. Ethyl acetate extract of a macrolichen 
Parmotrema tinctorum was shown to inhibit activity of α-
amylase with an IC50 value of 587.74±3.27μg/ml87.  
In a study, Vinayaka et al.88 investigated amylase inhibitory 
potential of six lichens viz. Everniastrum cirrhatum, Usnea 
sinensis, Ramalina conduplicans, Ramalina hossei, 
Parmotrema pseudotinctorum and Parmotrema tinctorum 
from Karnataka, India. Methanol extracts of all lichens 
displayed concentration dependent inhibitory activity 
against amylase. Extract of R. conduplicans was effective to 
highest extent. Valadbeigi and Shaddel89 screened inhibition 
of amylase activity by methanol extract of ten macrolichens 
of Mazandaran province, Iran. A concentration dependent 
inhibitory activity was observed and the activity of lichens 
was in the order: Usnea articulata > Ramalina pollinaria > R. 
hyrcana > Cladonia rei > Flavoparmelia caperata > 
Parmotrema chinense > Punctelia subrudecta > P. borreri > 
Hyperphyscia adglutinata > Peltigera praetextata. Karthik et 
al.90 showed a concentration dependent inhibition of 
amylase activity by methanolic extract of H. leucomela. At 
25mg/ml concentration, the extract caused 38.57% 
inhibition of enzyme activity.  
Glucosidase inhibitory activity 
Methanol extract of Caloplaca biatorina exhibited 
concentration dependent inhibition of α-glucosidase83. Ethyl 
acetate extract of Parmotrema tinctorum exhibited inhibitory 
activity against α-glucosidase with an IC50 value of 
58.45±1.24μg/ml87. Solvent extracts of lichens viz. 
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Herpothallon sp., Ramalina sinensis, Leptogium sp., 
Heterodermia leucomelos, Parmotrema tinctorum, P. crinitum, 
P. reticulatum and Cladonia subradiata were screened for β-
glucosidase inhibitory. Marked inhibition of glucosidase 
activity was displayed by lichens R. sinensis, H. leucomelos 
and Leptogium sp. while species of Parmotrema, in particular 
P. reticulatum, were not so effective91. In a study, lobaric acid 
isolated from methanol extract of Heterodermia sp. did not 
show inhibitory activity against α-glucosidase79. 
Karunaratne et al.78 evaluated α-glucosidase inhibitory 
activity of metabolites viz. zeorin, methyl β-
orcinolcarboxylate, methylorsellinate, atranorin and lobaric 
acid isolated from a Sri Lankan lichen Cladonia sp. Zeorin 
exhibited highest α-glucosidase inhibitory activity with an 
IC50 value of 100.0±0.3μM. Methyl β-orcinolcarboxylate and 
methylorsellinate showed inhibition of enzyme activity with 
IC50 value of 140.0±0.6 and 165.0±1.2μM, respectively. 
Atranorin and lobaric acid did not show α-glucosidase 
inhibitory properties. Verma et al.92 studied glucosidase 
inhibitory activity of solvent extracts of Ramalina celastri, R. 
nervulosa and R. pacifica. Extracts were effective in inhibiting 
α and β-glucosidases. Marked inhibitory activity was shown 
by methanol extract whereas acetone extract showed least 
activity. Ramalina derived metabolites viz. usnic acid, 
sekikaic acid and salazinic acid were shown to be effective 
against glucosidases with marked activity shown by sekikaic 
acid. Lee and Kim93 screened β-glucosidase inhibitory 
activity of extract of Umbilicaria esculenta. The extract 
caused strong inhibition of glucosidase of mammalian and 
mold origin. 1-deoxynojirimycin (1,5-dideoxy-1,5-immino-D-
glucitol) was shown to be the active component in the 
extract.  
Protein tyrosine phosphatase 1B (PTP1B) inhibitory 
activity 
Usnic acid and three usnic acid derivatives (Usimines A-C) 
were isolated from methanol extract of Stereocaulon 
alpinum. The compounds have shown moderate inhibitory 
activity against PTP1B94. Methanol extract of an Antarctic 
lichen Umbilicaria antarctica was shown to exhibit 
significant inhibitory activity against PTP1B. Three 
compounds viz. gyrophoric acid, lecanoric acid and methyl 
orsellinate, isolated from the lichen exhibited PTP1B 
inhibitory activity with IC50 value of 3.6±0.04μM, 31±2.7μM, 
and 277±8.6μM, respectively95. Lobaric acid and two 
pseudodepsidone-type compounds (2 and 3), isolated from 
methanol extract of S. alpinum showed potent inhibitory 
activity against PTP1B with IC50 values of 0.87μM, 6.86μM, 
and 2.48μM, respectively96. Four diterpene furanoids 
compounds designated as hueafuranoids A-D were isolated 
from the methanol extract of Huea sp. Hueafuranoid A 
displayed inhibitory activity (in a noncompetitive manner) 
against PTP1B with an IC50 value of 13.9μM76. Compounds 
viz. hopane-6α,22-diol, brialmontin 1, and atraric acid, 
isolated from the methanolic extract of an Antarctic lichen 
Lecidella carpathica, showed inhibitory activity against 
PTP1B dose-dependently with an IC50 values of 3.7, 14.0 and 
51.5μM, respectively97. 
Tyrosinase inhibitory activity 
In the study of Higuchi et al.98, the methanol extracts 
obtained from tissues (from axenic cultures) of Hypogymnia 
physodes, Letharia vulpina, and Cetraria juniperina were 
shown to strongly inhibit tyrosinase activity, however, the 
extracts of the corresponding natural thalli of lichens 
revealed weaker inhibitory activity. In case of Hypogymnia 
physodes, the mycobiont exhibited a higher inhibitory 
potential when compared to the photobiont. Behera et al.99 
investigated the potential of some graphidaceous lichens 
against tyrosinase enzyme activity. Methanolic extracts of 
lichens viz. Graphina glaucorufa, G. multistriata, G. 
salacinilabiata, Graphis assamensis, G. nakanishiana and 
Phaeographopsis indica exhibited inhibitory activity against 
tyrosinase with IC50 value of 9.32, 8.40, 6.82, 10.06, 7.91 and 
10.35µg/ml, respectively. Behera et al.100 also showed 
inhibitory activity against tyrosinase by lichen species such 
as Graphina glaucorufa, G. multistriata, G. salacinilabiata, 
Graphis assamensis, G. nakanishiana, and Phaeographopsis 
indica. Methanol extracts were more effective than other 
extracts. Behera et al.101 found inhibitory activity of 
methanol extract of natural thalli and in vitro grown cultures 
of Graphis guimarana, G. nakanishiana and G. schizograpta 
against tyrosinase. The study of Paudel et al.102 revealed the 
anti-tyrosinase activity of a compound designated as 
Ramalin, isolated from the lichen Ramalina terebrata. The 
compound was more potent than kojic acid. In a similar 
study, Chang et al.103 reported the melanogenesis inhibition 
by Ramalin, produced by R. terebrata, through its inhibitory 
activity against tyrosinase and by down-regulation of 
melanogenic proteins.  
Orsellinates, the derivatives of lecanoric acid isolated from 
Parmotrema tinctorum, were shown to exhibit inhibitory 
activity against mushroom tyrosinase. Other compounds viz. 
orcinol, resorcinol and orsellinic acid were also effective 
against tyrosinase activity104. Behera and Makhija105 
determined tyrosinase inhibitory activity of extracts from 
natural thallus as well as in vitro grown cultures of the lichen 
Bulbothrix setschwanensis. Extracts were effective in causing 
inhibition of enzyme with IC50 values of >18%. Extract from 
natural thallus inhibited the enzyme with an IC50 value of 
26.1µg/ml. The study carried out by Verma et al.46 revealed 
tyrosinase inhibitory activity of extracts from cultured 
lichen-symbionts of three lichens viz. Arthothelium awasthii 
(IC50 value 8.71µg/ml), Heterodermia podocarpa (IC50 value 
14.55µg/ml) and Parmotrema tinctorum (IC50 value 
12.44µg/ml). Honda et al.106 showed tyrosinase inhibitory 
activity of the extracts of lichens viz. Cladia aggregata, 
Cladonia dimorphoclada, Stereocaulon ramulosum and 
Stereocaulon microcarpum. Highest and least activity was 
exhibited by extract of S. microcarpum (32.4% inhibition) 
and C. dimorphoclada (16.1% inhibition), respectively. Kim 
and Cho107 evaluated tyrosinase inhibitory activity of 
methanolic extracts of Umbilicaria esculenta and Usnea 
longissima. The inhibitory activity of U. esculenta and U. 
longissima was shown to be 67.4% and 84.8%, respectively. 
The study revealed that the extracts showed the activity via 
the inhibition of tyrosinase glycosylation. The study of 
Matsubara et al.108 showed anti-tyrosinase activity of lichen 
metabolite resorcinol and its synthetic analogues. One of the 
analogues, 4-alkylresorcinols, displayed strong inhibitory 
activity.  
Xanthine oxidase inhibitory activity 
Methanol extract from the lichen Caloplaca biatorina was 
tested for inhibitory activity against xanthine oxidase. The 
lichen extract exhibited a concentration dependent inhibition 
of the enzyme83. The methanolic extracts obtained from 
some Graphidaceae members were inhibitory against 
xanthine oxidase with an IC50 value ranging from 2.0 to 
5.26µg/ml109. Methanolic extract of some graphidaceous 
lichens viz. Graphina glaucorufa, G. multistriata, G. 
salacinilabiata, Graphis assamensis, G. nakanishiana and 
Phaeographopsis indica were shown to display inhibitory 
activity against xanthine oxidase with an IC50 value of 3.4, 
4.8, 2.9, 6.8, 8.6 and 3.6µg/ml, respectively99. Behera et al.101 
showed inhibitory activity of methanol extract of natural 
thalli and in vitro grown cultures of Graphis guimarana, G. 
nakanishiana and G. schizograpta against xanthine oxidase. 
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Behera and Makhija105 screened xanthine oxidase inhibitory 
activity of extracts obtained from natural thallus and in vitro 
grown cultures of the lichen Bulbothrix setschwanensis. 
Extracts were effective in causing inhibition of enzyme with 
IC50 values of >40%. Extract from natural thallus inhibited 
xanthine oxidase with an IC50 value of 52.1µg/ml. Xu et al.110 
isolated a new pheophytin, (132S, 17S, 18S)-132-hydroxy-
20-chloro-ethylpheophorbide together with two known 
analogues from Usnea diffracta and evaluated their 
inhibitory activity against xanthine oxidase. The compounds 
showed significant inhibitory activity against xanthine 
oxidase. 
Inhibition of fatty acid synthase activity 
The study of Bessadottir et al.111 showed that the treatment 
with (+)-protolichesterinic acid in SK-BR-3 cells results in 
overexpression of fatty acid synthase indicating the primary 
effect of the compound on the activity of fatty acid synthase. 
Lauinger et al.77 studied the potential of four lichen 
compounds namely evernic acid, vulpic acid, (+)-usnic acid 
and psoromic acid to inhibit the enzymes involved in fatty 
acid biosynthesis pathway. Compounds viz. vulpic acid, 
evernic acid, (+)-usnic acid displayed inhibition of one or 
more enzymes of fatty acid biosynthesis pathway.  
Cholinesterase inhibitory activity 
A mixture of acetylated depsidones with moderate inhibitory 
activity against acetylcholinesterase were isolated from a 
foliose lichen by Pejin et al.112. Perlatolic acid, a lichen 
derived compound, is shown to exhibit promising 
acetylcholine esterase inhibition activity113. A depsidone 
compound isolated from the foliose lichen Lobaria 
pulmonaria was shown to exert moderate inhibitory activity 
against acetylcholinesterase114. Lobaric acid, isolated from 
Heterodermia sp. was shown to exhibit inhibitory activity 
against acetyl-cholinesterase with an IC50 value of 26.86μM 
and butyryl-cholinesterase with an IC50 value of 36.76μM79. 
Biruloquinone, a compound isolated from the lichen forming 
fungus Cladonia mucilenta, was screened for 
acetylcholinesterase inhibitory activity. The compound 
exhibited dose dependent inhibitory activity against the 
enzyme with an IC50 value of 27.1μg/ml115. 
Lipoxygenase inhibitory activity 
Ingolfsdottir et al.116 isolated protolichesterinic acid from 
Cetraria islandica and screened its activity against 5-
lipoxygenase in vitro. The compound was shown to exhibit 
inhibitory activity against the enzyme 5-lipoxygenase. Two 
isomeric compounds namely (+)-lichesterinic acid and (-)-
lichesterinic acid, synthesized from (+)-protolichesterinic- 
and (-)-allo-protolichesterinic acids, respectively, were also 
effective against 5-lipoxygenase activity. Ingolfsdottir et 
al.117 recovered a lichen substance from Stereocaulon 
alpinum and screened for enzyme inhibitory activity. The 
compound was identified as lobaric acid and was shown to 
display concentration dependent inhibitory activity with an 
IC50 value of 7.3µM. Ingolfsdottir et al.118 isolated 
Baeomycesic acid from Thamnolia subuliformis and found its 
potent concentration dependent inhibitory activity against 5-
lipoxygenase with an IC50 value of 8.3 μM. An alkamide 
designated as 9-cis-octa-decenamide was isolated from the 
lichen Stereocaulon alpinum. The compound was shown to 
display only slight activity against 5-lipoxygenase119. The 
lichen compounds imbricaric acid and perlatolic acid, 
isolated from the lichen Cetrelia monachorum, were effective 
against 5-lipoxygenase with and IC50 value of 5.3 and 1.8µM, 
respectively120.  
Two orcinol derivatives viz. tenuiorin and methyl orsellinate, 
isolated from the lichen Peltigera leucophlebia were shown 
to exhibit inhibitory activity against 15-lipoxygenase from 
soybeans in vitro. Tenuiorin and methyl orsellinate were also 
moderately effective against 5-lipoxygenase (from porcine 
leucocytes) with IC50 values of 41.6μM and 59.6μM, 
respectively121. Lichen compounds viz. protolichesterinic 
acid, lobaric acid and baeomycesic acid exhibit inhibitory 
activity against 5-lipoxygenase. Protolichesterinic acid and 
lobaric acid also exhibit 12-lipoxygenase activity122. Lichen 
metabolites viz. lobaric acid, (+)-protolichesterinic acid and 
baeomycesic acid, isolated from Stereocaulon alpinum, 
Cetraria islandica and Thamnolia vermicularis, respectively 
were screened for inhibitory activity on platelet-type 12(S)-
lipoxygenase. The compounds lobaric acid and (+)-
protolichesterinic acid showed pronounced inhibitory 
activity against the enzyme while baeomycesic acid caused 
slight activity123. Behera et al.124 determined anti-
lipoxygenase activity of ethyl acetate extract of 8 
Heterodermia sp. Extracts were effective in causing dose 
dependent inhibition of lipoxygenase with IC50 value of 
0.123, 0.187, 0.187, 0.153, 0.160, 0.229, 0.150 and 
0.232mg/ml in case of H. diademata, H. angustiloba, H. 
albicans, H. flabellata, H. antillarum, H. isidiophora, H. incana 
and H. pseudospeciosa, respectively.  
Cyclooxygenase (COX) inhibitory activity 
Two compounds viz. atranorin and chloroatranorin, isolated 
from hexane extract of Parmotrema saccatilobum inhibited 
COX-1 and COX-2 enzymes in a dose dependent manner125. 
Lobaric acid and atranorin, isolated from Stereocaulon 
alpinum, were screened for inhibitory activity against 
cyclooxygenase. Lobaric acid showed inhibitory activity (IC50 
value 29.2μM) while atranorin was found to be inactive117. 
An alkamide designated as 9-cis-octa-decenamide, isolated 
from the lichen Stereocaulon alpinum, was shown to display 
inhibitory activity against cyclooxygenase from sheep 
seminal vesicle microsomes with an IC50 value of 64.3μM119. 
Jager et al.126 evaluated inhibitory potential of extracts of 
some lichens against prostaglandin-synthesis through 
inhibitory activity against cyclooxygenase. Ethanol extract of 
Pseudocyphellaria aurata caused highest inhibition of 96%. 
Extracts of Parmelia autrosinensis, P. reticulata, P. soredians, 
Heterodermia speciosa, Usnea undulata and Ramalina celastri 
also revealed promising inhibitory activity. Through in silico 
molecular docking studies, Khan et al.127 highlighted the 
possible inhibitory role of lichen metabolites such as 
atranorin, lecanoric acid, and diffractic acid against 
cyclooxygenase-2 enzyme. The study of Engel et al.128 
revealed anti-inflammatory properties of U. barbata in an 
ultraviolet-B model with HaCaT keratinocytes. Extract 
inhibited prostaglandin E2 synthesis through an effect on 
COX-2 activity rather than on protein expression.  
Prolyl endopeptidase inhibitory activity 
Extract of a Himalayan lichen Cetrelia olivetorum was 
screened for inhibitory activity against Prolyl endopeptidase. 
The extract caused inhibition of the enzyme with an IC50 
value of 144-288 µg/ml129. 
Inhibitory activity against Phospholipase A2 
Two depside compounds viz. orcinol and methyl orsellinic 
acid, isolated from the methanol extract of Umbilicaria 
esculenta, were shown to inhibit human synovial fluid 
Phospholipase A2130. 
Inhibition of Prostaglandin E2 synthase-1 activity 
Oettl et al.120 isolated two compounds viz. imbricaric acid 
and perlatolic acid from the lichen Cetrelia monachorum and 
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screened them for inhibitory activity against Prostaglandin 
E2 synthase-1. Both imbricaric acid and perlatolic acid were 
effective and showed inhibition of the enzyme with an IC50 
value of 1.9 and 0.4µM, respectively. Through validated 
pharmacophore models (cell free assays), Bauer et al.131 
revealed physodic acid and perlatolic acid as potent 
inhibitors of Prostaglandin E2 synthase-1 with IC50 values of 
0.4 and 0.43μM, respectively. 
Aldehyde oxidase inhibitory activity 
Valadbeigi83 screened methanol extract obtained from 
Caloplaca biatorina for inhibitory activity against aldehyde 
oxidase enzyme. The extract was shown to exhibit 
concentration dependent inhibition of aldehyde oxidase. 
Aldose reductase inhibitory activity 
Ethyl acetate extract of a macrolichen Parmotrema tinctorum 
was found to exhibit inhibitory activity against aldose 
reductase with an IC50 value of 139.28±2.6μg/ml87. 
Inhibition of DNA polymerases 
Le et al.132 isolated eight new alkylated decalin-type 
polyketides from the mycobiont of a crustose lichen Pyrenula 
sp. The polyketide compounds (1 and 7) showed inhibitory 
activities against mammalian DNA polymerases α and β with 
IC50 values ranging from 8.1 to 19.5μM.  
Pancreatic lipase inhibitory activity 
Kumar et al.28 investigated anti-obesity activity of methanol 
extract of Everniastrum cirrhatum in terms of inhibition of 
chicken pancreatic lipase. The extract was effective and was 
shown to inhibit lipase activity in a concentration dependent 
manner. Shivanna et al.133 screened ethyl acetate and 
methanol extracts of two lichens viz. Heterodermia 
leucomelos and Ramalina celastri against chicken pancreatic 
lipase activity. Extracts were effective against enzyme 
activity in a concentration dependent manner. Methanol 
extracts were effective to more extent than ethyl acetate 
extracts.  
Plk1 inhibitory activity 
Williams et al.75 isolated a new depside and two known 
depsides from Parmotrema sp. and subjected these 
compounds for their inhibitory efficacy against Plk1 (polo-
like kinase-1). The new depside, β-collatolic acid and β-
alectoronic acid showed inhibitory effect against Plk1 with 
IC50 value of 2.8, 0.7, and 1.7μM, respectively.  
Topoisomerase inhibitory activity 
A depside compound Anziaic acid was isolated from 
Hypotrachyna sp. and evaluated for its topoisomerase 
inhibitory activity. The compound was effective in causing 
inhibition of E. coli and Y. pestis Topo 1with IC50 value 14-
19μM. Anziaic acid was also effective against human 
topoisomerase II but had little effect on human 
topoisomerase I40.  
β-glucuronidase inhibitory activity 
Lobaric acid, isolated from Heterodermia sp. was shown to 
exhibit inhibitory activity against β-glucuronidase with an 
IC50 value of 3.28±0.05μM79. 
Inhibitory activity against phosphodiesterase  
Lobaric acid, isolated from Heterodermia sp., caused 
significant inhibition of phosphodiesterase enzyme with an 
IC50 value 313.7±2.2μM79. 
 
Urease inhibitory activity 
Metabolites namely (S)-(−)-usnic acid and fumarproto-
cetraric acid, isolated from Cladonia rappii were shown to be 
active against jack bean urease. The compounds were 
effective in their interaction with the urease134. Compounds 
viz. ethyl heamatomate, atraric acid, ethyl orsellinate, 
lecanoric acid, gyrophoric acid, and licanorin isolated from 
Parmotrema cooperi were shown to exhibit inhibitory 
activitiy against urease with IC50 value of 42.13, 16.50, 50.83, 
67.20, 52.53 and 34.06μM, respectively. Orsellinic acid was 
not effective in causing inhibition of urease17. Thadhani et 
al.79 isolated lobaric acid from Heterodermia sp. and 
evaluated its inhibitory activity against urease. The 
metabolites was not effective in causing inhibition of urease. 
The study of Aydin et al.135 revealed dose dependent 
inhibition of urease enzyme by ethanol and ethyl acetate 
extracts of the lichen Usnea longissima. Ethanol extract was 
more effective than ethyl acetate extract.  
Inhibitory activity against Trypsin 
Proksa et al.136 isolated compounds viz. atranorin, physodic 
acid, oxyphysodic acid and virensic acid from a lichen species 
Pseudevernia furfuracea. The compound atranorin was 
shown to be the strongest inhibitor of trypsin. 
Thioredoxin reductase inhibitory activity 
The inhibitory effect of some lichen acids including 
diffractaic acid, evernic acid, lobaric acid, lecanoric acid, and 
vulpinic acid against the activity of thioredoxin reductase 
purified from rat lung was investigated137. All the tested 
compounds displayed marked effect on enzyme activity with 
stronger inhibitory activity displayed by lecanoric acid and 
vulpinic acid. 
Elastase inhibitory activity 
Atranorin, isolated from the lichen Pseudevernia furfuracea 
was shown to exhibit strong inhibitory activity against 
porcine pancreatic elastase136. Aydin et al.135 showed 
concentration dependent inhibition of elastase enzyme by 
ethanol and ethyl acetate extracts of Usnea longissima. 
Ethanol extract caused marked inhibitory activity than ethyl 
acetae extract.  
Inhibition of hydroxy-3-methyl-glutaryl-CoA reductase 
(HMGR) 
Behera et al.38 screened extracts of Usnea complanata and 
isolated compounds viz. usnic acid and psoromic acid for 
inhibitory activity against HMGR. Ethyl acetate and methanol 
extracts of the lichen were shown to display 74.81% and 
65.18% inhibition of HMGR. Usnic acid and psoromic acid 
were also effective in causing inhibition of HMGR in 
noncompetitive and competitive type. Mahadik et al.138 
showed dose dependent inhibition of HMGR by solvent 
extracts of U. complanata. At 200µg/ml concentration, the 
enzyme inhibition by extracts was in the order: ethyl acetate 
> methanol > ethanol > acetone extract.  
Inhibition of angiotensin converting enzyme (ACE) 
In a study, methanol, acetone, and ethanol extracts of Usnea 
complanata were shown to inhibit ACE by 43.47%, 23.18% 
and 21.73% respectively. Two compounds viz. usnic acid and 
psoromic acid, isolated from U. complanata, were effective in 
causing inhibition of ACE in uncompetitive and mixed type38. 
At 200µg/ml concentration, an inhibition of 46.4%, 44.3%, 
23.2% and 16% of ACE was produced by ethanol, ethyl 
acetate, methanol and acetone extract of U. complanata138. 
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Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitory 
activity 
Usnic acid derivatives were shown to exhibit Tdp1 inhibitory 
potential. Zakharenko et al.139 (2016) synthesized and 
tested novel usnic acid derivatives with an enamine moiety 
for inhibitory activity against Tdp1 enzyme. The enamines 
were effective with IC50 values in the range 0.16-2.0μM. 
Zakharova et al.140 screened 29 derivatives of (+)-usnic acid 
against Tdp1 inhibitory activity using a fluorescent-based 
assay. One of the derivatives i.e. 6m showed activity the 
lowest IC50 value of 25nM. Dyrkheeva et al.141 synthesized a 
series of usnic acid derivatives comprising a terpenoid 
moiety and subjected them for activity against Tdp1 enzyme. 
Compounds viz. 15A, 15B, 15G, 16A, 16B, and 16G were 
effective with IC50 values in the range 0.33 - 2.7µM. The 
inhibitory activities were shown to be dependent on the 
length and flexibility of the terpenoid moiety. 
Inhibition of sulfatase and aromatase activity 
Ingólfsdóttir et al.142 evaluated inhibition of estrogen 
formation through inhibition of two enzymes sulfatase and 
aromatase. An inhibitory activity of 83%, 95% and 90% 
against sulfatase was observed in case of extracts of Cladonia 
gracilis, Sphaerophorus fragilis and S. globosus, respectively. 
Extracts of Cetrariella delisei, Melanelia hepatizon and S. 
globosus caused 82%, 73% and 74% inhibition of aromatase, 
respectively. 
Telomerase inhibitory activity 
In a study, ethyl acetate, hexane and aqueous extracts 
obtained from the lichen Umbilicaria esculenta displayed 
strong inhibitory activity against telomerase143.  
Inhibition of Rab geranylgeranyl transferase activity 
The study carried out by Deraeve et al.144 revealed the 
potential of psoromic acid to inhibit the enzyme Rab 
geranylgeranyl transferase. The compound was effective and 
selectively inhibited the activity of the enzyme with an IC50 of 
1.3μM.  
Anti-UGM activity 
Psoromic acid, a lichen derived compound, was shown to 
exhibit marked inhibitory activity against UDP-
galactopyranose mutase (UGM) associated with 
Mycobacterium tuberculosis. An inhibition of 85.8% of UGM 
was observed145. 
Arylamine-N-acetyltransferase inhibitory activity 
Psoromic acid, a lichen derived compound, was shown to 
exhibit marked inhibitory activity against Arylamine-N-
acetyltransferase associated with Mycobacterium 
tuberculosis. The compound caused an inhibition of 77.4% of 
the enzyme with an IC50 value of 8.7µM145. 
Inhibition of HIV-1 reverse transcriptase 
In a study by Pengsuparp et al.146, protolichesterinic acid 
from the lichen Cetraria islandica, was shown to inhibit the 
activity of HIV-1 reverse transcriptase with an IC50 value of 
24μM. 
Monoamine oxidase inhibitory activity 
Okuyama et al.147 evaluated the inhibitory potential of three  
anthraquinones viz. averantin 6-monomethyl ether, solorinic 
acid, and 4,4'-bissolorinic acid, and two depsides namely 
methyl gyrophorate and gyrophoric acid, isolated from a 
lichen, Solorina crocea,  against monoamine oxidase. Only 
anthraquinones were shown to display inhibition of 
monoamine oxidase enzyme. Kinoshita et al.148 revealed the 
monoamine oxidase inhibitory activity of lichen metabolites 
and their synthetic analogues. One compound designated as 
4-acylresorcinol displayed potent inhibitory activity with 
IC50 value 4.27x10-6M. 
p-hydroxyphenylpyruvate dioxygenase inhibitory 
activity 
Romagni et al.14 showed phytotoxic activity of usnic acid 
isolated from Alectoria sarmentosa (Ach.) in terms of 
irreversible inhibition of activity of p-
hydroxyphenylpyruvate dioxygenase (with an apparent IC50 
value of 70nM). Treatment with the compound (-)-usnic acid 
resulted in a concentration dependent bleaching of the 
cotyledonary tissues together with a decrease of chlorophylls 
as well as carotenoids. However, least bleaching effect was 
observed in case of (+) enantiomer of usnic acid.  
CONCLUSIONS 
Natural products have been extensively screened for enzyme 
inhibition studies. Extensive literature survey carried out in 
this study revealed the potential of lichen extracts and 
purified metabolites from lichens to inhibit a range of 
enzymes such as lipase, amylase, glucosidase, urease, 
tyrosinase, xanthine oxidase, sulfatase, aromatase, elastase, 
monoamine oxidase, lipoxygenase, ACE, Tdp1, UDP-
galactopyranose mutase, thioredoxin reductase, HIV-1 
reverse transcriptase, trypsin, phosphodiesterase, 
telomerase, and topoisomerase. Lichens appears to be 
promising candidates for development of novel enzyme 
inhibitors which can be utilized as a remedy against various 
diseases and disorders. Studies concerning in vitro 
propagation of lichen symbionts for isolation of bioactive 
components with enzyme inhibitory activity may be 
undertaken.  
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